Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States

Leukemia. 2024 Feb;38(2):435-437. doi: 10.1038/s41375-023-02100-x. Epub 2023 Dec 4.

Authors

Ludovic Saba¹, Kevin S Landau¹, Hong Liang², Chieh-Lin Fu¹, Chakra P Chaulagain³

Affiliations

¹ Department of Hematology and Oncology, Myeloma and Amyloidosis Program, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, USA.
² Department of Clinical Research, Cleveland Clinic Florida, Weston, FL, USA.
³ Department of Hematology and Oncology, Myeloma and Amyloidosis Program, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, USA. CHAULAC@ccf.org.

PMID: 38049508
DOI: 10.1038/s41375-023-02100-x

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Leukemia, Lymphocytic, Chronic, B-Cell*
Leukemia, Plasma Cell*
Retrospective Studies
SEER Program
United States / epidemiology